Previously recorded as True North Therapeutics, Inc. (to 2017)
17 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2033. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2033
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2033 · Medium confidence
Also notable
Ends Oct 2033 · Medium confidence
Also notable
Ends May 2036 · Medium confidence
Also notable
Ends Oct 2038 · High confidence
Also notable
Ends Oct 2037 · High confidence
Anti-Complement C1S Antibodies
US 8,945,562
The most cited patent in this portfolio, cited by 40 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
ANTI-COMPLEMENT C1S ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITY
US 9,512,233
Cited by 23 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Polynucleotides Encoding ANTI-C1S Antibodies
US 11,246,926
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.
Methods of Inducing Complement Activity
US 11,192,944
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
ANTI-C1S Antibodies and Methods of Use Thereof
US 12,391,750
Granted 2025. Too new for citation comparison; protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 7, 2027
- 2 fees due Apr 22 to 29, 2027 · next Apr 22
- 1 fee due Jun 8, 2027The maintenance fee for Methods of Inhibiting Complement C4 Activation with Anti-Complement C1S Antibodies (US 9,206,259) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Complement C1S Antibodies | 8 in force | to Feb 2036 |
| ANTI-COMPLEMENT C1s ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITY | 4 in force | to Oct 2033 |
| HUMANIZED ANTI-C1s ANTIBODIES AND METHODS OF INHIBITING C1s CLEAVAGE | 2 in force | to Oct 2036 |
| Methods of Inducing Complement Activity | 1 in force | to Oct 2038 |
| ANTI-C1S Antibodies and Methods of Use Thereof | 1 in force | to Oct 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,512,233 | ANTI-COMPLEMENT C1S ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITY In force · Medium confidence | In force | Medium confidence | |
| US 9,562,092 | METHODS OF INHIBITING COMPLEMENT C4 ACTIVATION WITH ANTI-COMPLEMENT C1s ANTIBODIES In force · Medium confidence | In force | Medium confidence | |
| US 9,562,106 | ANTI-COMPLEMENT C1s ANTIBODIES AND METHODS OF INHIBITING COMPLEMENT C1s ACTIVITY In force · Medium confidence | In force | Medium confidence | |
| US 10,457,745 | ANTI-COMPLEMENT C1s ANTIBODIES In force · Medium confidence | In force | Medium confidence | |
| US 12,215,169 | Anti-Complement C1S Antibodies and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,945,562 | Anti-Complement C1S Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,074,003 | METHODS OF INHIBITING ACTIVATION OF COMPLEMENT COMPONENT C4 WITH ANTI-C1s ANTIBODIES In force · Medium confidence | In force | Medium confidence | |
| US 9,074,004 | Methods of Inhibiting Activation of Complement Component C4 with ANTI-C1S Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,206,259 | Methods of Inhibiting Complement C4 Activation with Anti-Complement C1S Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 10,450,382 | ANTI-COMPLEMENT C1s ANTIBODIES In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 17: 2 patents in force now held by others · 9 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.